Litigation Details for KING PHARMACEUTICALS INC. v. SANDOZ INC. (D.N.J. 2009)

KING PHARMACEUTICALS INC. v. SANDOZ INC. (D.N.J. 2009)

Docket		Date Filed	2009-07-21
Court	District Court, D. New Jersey	Date Terminated	2012-06-20
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand		Referred To	Karen M. Williams
Parties	SANDOZ INC.
Patents	6,066,339
Link to Docket	External link to docket

Details for KING PHARMACEUTICALS INC. v. SANDOZ INC. (D.N.J. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-07-21				External link to document

King Pharmaceuticals v. Sandoz Patent Litigation: Case No. 2:09-cv-03587

Last updated: September 25, 2026

King Pharmaceuticals, Inc. v. Sandoz Inc., No. 2:09-cv-03587, was an ANDA patent case in the U.S. District Court for the District of New Jersey involving Sandoz’s proposed generic version of King’s Skelaxin product, whose active ingredient is metaxalone. King asserted Orange Book-listed patents covering metaxalone tablets and related pharmaceutical compositions. The case was resolved before a reported merits judgment, so it did not produce a definitive district-court ruling invalidating or upholding the asserted patent claims.

What drug and patents were involved in King v. Sandoz?

The case concerned Skelaxin, a prescription muscle relaxant containing metaxalone. King marketed Skelaxin tablets in 400-mg and 800-mg strengths. Sandoz filed an Abbreviated New Drug Application seeking approval to market generic metaxalone tablets.

King’s asserted patent position centered on U.S. Patent No. 6,407,128. The patent covered metaxalone pharmaceutical compositions and related methods of use. The patent was listed in the FDA’s Orange Book for Skelaxin and had a term extending into the early 2020s, subject to statutory adjustments and any applicable regulatory exclusivity provisions.

Item	Case information
Plaintiff	King Pharmaceuticals, Inc.
Defendant	Sandoz Inc.
Court	U.S. District Court for the District of New Jersey
Civil action	No. 2:09-cv-03587
Product	Skelaxin
Active ingredient	Metaxalone
Regulatory pathway	ANDA
Legal basis	Hatch-Waxman patent infringement
Principal patent	U.S. Patent No. 6,407,128
Patent category	Composition, formulation, and use claims relating to metaxalone
Litigation posture	ANDA litigation resolved before a reported merits trial judgment

The case was part of a broader generic-entry dispute involving metaxalone. King’s commercial position depended on enforcing the Orange Book patent listed for Skelaxin against Sandoz’s proposed generic product.

What triggered the King Pharmaceuticals patent lawsuit?

Sandoz’s ANDA included a Paragraph IV certification challenging the patent protection associated with Skelaxin. A Paragraph IV certification states that an Orange Book-listed patent is invalid, unenforceable, or not infringed by the proposed generic product.

King responded by filing an infringement action under 35 U.S.C. § 271(e)(2). That statutory claim allows a branded drug company to sue when an ANDA applicant seeks FDA approval for a product that would infringe a listed patent if commercially made, used, or sold.

The filing of the action generally triggered the Hatch-Waxman 30-month stay of FDA approval, unless the case was resolved earlier or the stay was modified or terminated by court order. The litigation therefore affected the timing of Sandoz’s potential generic launch even before any trial or final patent decision.

What were the main patent issues?

Validity of the metaxalone patent

The central validity questions in an ANDA case of this type would include:

• Whether the claimed metaxalone composition was anticipated by earlier disclosures.
• Whether the claimed formulation or use would have been obvious to a person skilled in the pharmaceutical arts.
• Whether the patent specification adequately described and enabled the claimed subject matter.
• Whether the asserted claims satisfied statutory definiteness requirements.

Metaxalone had been known as an active pharmaceutical ingredient before the patent at issue. The commercial value of the patent therefore depended less on ownership of the molecule itself and more on the scope of the claimed composition, dosage form, formulation, or use.

Infringement

King’s infringement case depended on the contents of Sandoz’s ANDA and the proposed product labeling. In Hatch-Waxman litigation, the court can assess infringement based on the generic product described in the ANDA without waiting for commercial launch.

Potential infringement theories included:

• Direct infringement of composition claims.
• Infringement based on the formulation and dosage form.
• Induced infringement based on the proposed generic labeling.
• Infringement of method-of-use claims if the labeling encouraged a patented use.

For a relatively conventional oral tablet, the decisive issue is often claim scope. A broad claim covering metaxalone tablets may create a stronger barrier than a narrow claim limited to a particular excipient, release profile, or manufacturing parameter.

Claim construction

The parties’ dispute also required construction of technical patent terms. In pharmaceutical cases, claim construction can determine whether the asserted claims reach the generic product described in the ANDA. Terms relating to pharmaceutical composition, dosage amount, excipients, tablet characteristics, and therapeutic use can materially affect the infringement analysis.

No widely cited Federal Circuit opinion from this docket established a controlling construction for the Skelaxin patent claims. The case therefore has limited precedential value compared with ANDA cases that proceeded to appeal.

What was the litigation timeline?

Date or period	Event
2009	King filed the patent infringement action against Sandoz in the District of New Jersey.
2009-2010	The parties litigated the ANDA-based infringement claims and patent defenses.
2010	District-court procedural and claim-construction activity occurred in the case.
Before a reported merits judgment	The dispute was resolved, ending the need for a trial on validity and infringement.
Subsequent period	Generic metaxalone products entered the U.S. market through the broader ANDA approval and settlement landscape.

The public case record does not provide a reported trial verdict establishing that U.S. Patent No. 6,407,128 was valid and infringed, or invalid and not infringed. The absence of a merits decision limits the case’s usefulness as authority on the patent’s substantive strength.

Did Sandoz win or lose the case?

Neither party obtained a reported merits victory. The litigation ended without a published decision holding the asserted patent valid and infringed or invalid and not infringed.

For commercial analysis, the more important result was the resolution of the generic-entry dispute. A settlement in an ANDA case may establish an agreed launch date or other market-access terms without resolving the underlying patent validity question. The public record does not establish a detailed set of settlement terms that would support a precise launch-date analysis.

The case should therefore be classified as a resolved ANDA dispute rather than as a precedent confirming the enforceability of King’s metaxalone patent.

What was the Orange Book status of Skelaxin?

Skelaxin’s Orange Book protection was based on patent listings associated with metaxalone tablets. The principal patent relevant to King v. Sandoz was U.S. Patent No. 6,407,128.

Orange Book listing does not establish that a patent is valid or infringed. It gives the patent procedural significance under the Hatch-Waxman Act by requiring an ANDA applicant to address the listed patent through a certification. The listing also allows the brand company to invoke the statutory approval stay by filing an infringement action within the required period.

The patent estate should be separated into three categories:

1. Active-ingredient protection: Limited or unavailable because metaxalone was an established compound.
2. Formulation and composition protection: The primary basis for the asserted Skelaxin patent.
3. Method-of-use protection: Relevant only to the extent that the listed claims covered an FDA-approved use and the generic label encouraged that use.

The Orange Book status did not guarantee long-term market exclusivity. Generic applicants could challenge the listed claims, design around narrower formulation limitations, or obtain approval after expiration or settlement-based market entry.

When did Skelaxin lose exclusivity?

Skelaxin’s practical exclusivity ended through a combination of patent expiry, generic challenges, and generic approvals rather than through a single regulatory date.

The principal patent, U.S. Patent No. 6,407,128, had an expiration date in the early 2020s based on its ordinary patent term. The commercial market saw generic metaxalone products before that nominal expiry through ANDA approvals and settlements involving generic manufacturers.

FDA approval of a generic does not necessarily mean that every listed patent has been judicially invalidated. A generic may enter under a settlement, after patent expiry, after a court ruling, or under other terms that eliminate the relevant legal barrier.

Skelaxin did not have the type of biologic exclusivity that applies to a reference biological product. The product was a small-molecule tablet, so biosimilar provisions under the Biologics Price Competition and Innovation Act were not relevant.

Were there Paragraph IV challenges to Skelaxin?

Yes. The King v. Sandoz litigation arose from Sandoz’s ANDA patent challenge, which included a Paragraph IV certification directed to the listed Skelaxin patent.

Paragraph IV litigation creates several commercial outcomes:

• A court may uphold the patent and delay approval until expiry.
• The court may find the patent invalid or not infringed.
• The parties may settle with an agreed generic launch date.
• The generic applicant may alter its product or labeling to avoid infringement.
• FDA approval may proceed after the statutory stay ends even if the patent remains listed.

The case’s resolution without a reported merits opinion means that the Paragraph IV challenge did not yield a judicial determination that can be used to score the patent as definitively strong or weak.

How strong was King’s patent estate?

King’s patent estate was commercially meaningful but structurally narrow compared with an estate built around a new chemical entity.

Strengths

• The patent was listed in the Orange Book.
• The patent supported a statutory infringement action against an ANDA applicant.
• The patent term extended beyond the date of the 2009 generic challenge.
• The claims were directed to a marketed pharmaceutical composition rather than an uncommercialized research concept.

Weaknesses

• Metaxalone was an established active ingredient.
• Formulation and composition claims generally face narrower claim scope than active-ingredient claims.
• A generic tablet manufacturer may challenge validity or avoid infringement through product design.
• Settlement rather than adjudication left the patent’s ultimate validity unresolved.
• Generic competition could begin before nominal patent expiry if the parties agreed to an early-entry date.

Overall, the patent estate was strong enough to impose litigation and delay risk on Sandoz, but the public record does not support treating it as a fully validated barrier through the end of its stated term.

What litigation affected generic metaxalone entry?

King v. Sandoz was one dispute in the generic metaxalone landscape. Other ANDA applicants also pursued generic Skelaxin products, creating a multi-applicant market-entry environment.

The main competitive factors were:

• The number of Paragraph IV filers.
• The timing of the first substantially complete ANDA.
• Whether settlements granted staggered or common entry dates.
• Whether generic products matched both the 400-mg and 800-mg strengths.
• The extent of price erosion after multiple approvals.
• Whether King could enforce formulation claims against alternative tablet designs.

Once several generic manufacturers received approval, the practical value of the remaining patent estate declined. A composition patent can delay entry, but it does not preserve branded pricing after multiple generic products become available.

Did the case involve manufacturing or formulation barriers?

The case’s value to King was tied primarily to formulation and composition protection rather than manufacturing exclusivity. A generic manufacturer could face infringement risk if its ANDA product fell within the patent claims, even if the manufacturing process differed.

Manufacturing-process patents would have created a separate barrier. They could be harder to enforce against a confidential process described only partially in an ANDA. The reported case is principally associated with the Skelaxin composition and formulation patent, not with a dominant process patent estate.

What are the commercial implications of King v. Sandoz?

King’s exposure was the erosion of Skelaxin revenue after generic metaxalone entry. The risk profile included:

• A temporary FDA approval stay after the lawsuit was filed.
• Potential acceleration of generic entry through settlement.
• Price declines after the first generic launch.
• Additional erosion after multiple generic approvals.
• Reduced leverage in licensing or settlement negotiations once competing ANDAs were filed.

Sandoz faced the opposite risk: delayed approval, litigation expense, possible damages exposure if it launched at risk, and the possibility of a patent term extending beyond its expected commercial launch window.

Because the case ended without a reported validity decision, it provided limited guidance for later parties evaluating the probability of invalidity, noninfringement, or settlement-based entry.

Key Takeaways

• King Pharmaceuticals sued Sandoz over an ANDA for generic metaxalone tablets, the active ingredient in Skelaxin.
• The principal patent was U.S. Patent No. 6,407,128, an Orange Book-listed patent directed to metaxalone compositions and related uses.
• The case was filed in the District of New Jersey as No. 2:09-cv-03587.
• Sandoz’s Paragraph IV challenge triggered Hatch-Waxman litigation and a potential FDA approval stay.
• The dispute ended without a reported merits ruling on patent validity or infringement.
• The case did not involve biosimilar competition because Skelaxin is a small-molecule drug.
• King’s estate provided meaningful litigation leverage but was narrower than a new-chemical-entity patent estate.
• Generic metaxalone entry and subsequent competition ultimately limited Skelaxin’s exclusivity and pricing power.

FAQs

Was King v. Sandoz a Hatch-Waxman lawsuit?

Yes. The action was based on Sandoz’s ANDA and King’s claims under 35 U.S.C. § 271(e)(2), making it a standard Hatch-Waxman patent dispute.

What was the active ingredient in the accused generic product?

The accused product contained metaxalone, the active ingredient in Skelaxin.

Was U.S. Patent No. 6,407,128 held invalid?

No reported merits decision from this case established that the patent was invalid. The litigation ended without a published trial judgment resolving validity.

Did the case create biosimilar litigation risk?

No. Biosimilar law was not relevant because metaxalone is a small-molecule active ingredient regulated through the ANDA pathway.

Did the lawsuit permanently block generic Skelaxin?

No. Generic metaxalone products ultimately entered the U.S. market. The lawsuit delayed or structured entry risk but did not create permanent exclusivity.

References

1. U.S. District Court for the District of New Jersey. (2009). King Pharmaceuticals, Inc. v. Sandoz Inc., No. 2:09-cv-03587.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations (Orange Book).

3. U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,407,128: Metaxalone compositions and methods of use.

4. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. §§ 355, 355(j).

5. Patent Act, 35 U.S.C. § 271(e)(2).